Neonatal lupus erythematosus

Naoto Yokogawa, Naofumi Sumitomo, Masaru Miura, Kazuhiko Shibuya, Hiroshi Nagai, Mikako Goto, Atsuko Murashima

Research output: Contribution to journalArticle

Abstract

Neonatal lupus (NL), a passively-acquired autoimmune disease associated with maternal anti-SSA antibody, presents both cardiac manifestations such as cardiac NL and non-cardiac manifestations including rashes, cytopenia, and hepatic abnormalities. Cardiac NL, occurring in 1-2% of anti-SS-A antibody-positive mothers, is a life-threatening complication with a mortality rate of 20% and a pacemaker implantation rate of 70%. In contrast, cutaneous NL, which is more common than cardiac NL, usually resolves in six months. Since half of NL cases occur in asymptomatic mothers, if an infant presents characteristic cutaneous or cardiac manifestations of NL, the mother should be tested for anti-SS-A antibody. In mothers positive for anti-SS-A antibody, the risk of having a child with cardiac NL increases ten-fold and five-fold for a previous child with cardiac NL and cutaneous NL, respectively. A joint American, British, and French retrospective study of NL registries showed that hydroxychloroquine (HCQ) reduced the cardiac NL risk in subsequent pregnancies in mothers who previously had a child with cardiac NL. A prospective open-label study to confirm this effect is being undertaken in the USA. A similar prospective multi-center study will be undertaken in Japan. Establishing a Japanese registry of children with NL and subsequent pregnancies of their mothers will help promote clinical research in NL in Japan.

Original languageEnglish
Pages (from-to)124-130
Number of pages7
JournalJapanese Journal of Clinical Immunology
Volume40
Issue number2
DOIs
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

Mothers
Neonatal Systemic lupus erythematosus
Skin
Registries
Japan
Hydroxychloroquine
Pregnancy
Exanthema
Autoimmune Diseases
Anti-Idiotypic Antibodies
Retrospective Studies
Joints
Mortality
Liver
Research
SS-A antibodies

Keywords

  • Anti-SS-A antibody
  • Congenital heart block
  • Hydroxychloroquine
  • Neonatal cutaneous lupus erythematosus
  • Neonatal lupus erythematosus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Yokogawa, N., Sumitomo, N., Miura, M., Shibuya, K., Nagai, H., Goto, M., & Murashima, A. (2017). Neonatal lupus erythematosus. Japanese Journal of Clinical Immunology, 40(2), 124-130. https://doi.org/10.2177/jsci.40.124

Neonatal lupus erythematosus. / Yokogawa, Naoto; Sumitomo, Naofumi; Miura, Masaru; Shibuya, Kazuhiko; Nagai, Hiroshi; Goto, Mikako; Murashima, Atsuko.

In: Japanese Journal of Clinical Immunology, Vol. 40, No. 2, 01.01.2017, p. 124-130.

Research output: Contribution to journalArticle

Yokogawa, N, Sumitomo, N, Miura, M, Shibuya, K, Nagai, H, Goto, M & Murashima, A 2017, 'Neonatal lupus erythematosus', Japanese Journal of Clinical Immunology, vol. 40, no. 2, pp. 124-130. https://doi.org/10.2177/jsci.40.124
Yokogawa N, Sumitomo N, Miura M, Shibuya K, Nagai H, Goto M et al. Neonatal lupus erythematosus. Japanese Journal of Clinical Immunology. 2017 Jan 1;40(2):124-130. https://doi.org/10.2177/jsci.40.124
Yokogawa, Naoto ; Sumitomo, Naofumi ; Miura, Masaru ; Shibuya, Kazuhiko ; Nagai, Hiroshi ; Goto, Mikako ; Murashima, Atsuko. / Neonatal lupus erythematosus. In: Japanese Journal of Clinical Immunology. 2017 ; Vol. 40, No. 2. pp. 124-130.
@article{ae89b94edac84fd2a05e5df53eb7d43a,
title = "Neonatal lupus erythematosus",
abstract = "Neonatal lupus (NL), a passively-acquired autoimmune disease associated with maternal anti-SSA antibody, presents both cardiac manifestations such as cardiac NL and non-cardiac manifestations including rashes, cytopenia, and hepatic abnormalities. Cardiac NL, occurring in 1-2{\%} of anti-SS-A antibody-positive mothers, is a life-threatening complication with a mortality rate of 20{\%} and a pacemaker implantation rate of 70{\%}. In contrast, cutaneous NL, which is more common than cardiac NL, usually resolves in six months. Since half of NL cases occur in asymptomatic mothers, if an infant presents characteristic cutaneous or cardiac manifestations of NL, the mother should be tested for anti-SS-A antibody. In mothers positive for anti-SS-A antibody, the risk of having a child with cardiac NL increases ten-fold and five-fold for a previous child with cardiac NL and cutaneous NL, respectively. A joint American, British, and French retrospective study of NL registries showed that hydroxychloroquine (HCQ) reduced the cardiac NL risk in subsequent pregnancies in mothers who previously had a child with cardiac NL. A prospective open-label study to confirm this effect is being undertaken in the USA. A similar prospective multi-center study will be undertaken in Japan. Establishing a Japanese registry of children with NL and subsequent pregnancies of their mothers will help promote clinical research in NL in Japan.",
keywords = "Anti-SS-A antibody, Congenital heart block, Hydroxychloroquine, Neonatal cutaneous lupus erythematosus, Neonatal lupus erythematosus",
author = "Naoto Yokogawa and Naofumi Sumitomo and Masaru Miura and Kazuhiko Shibuya and Hiroshi Nagai and Mikako Goto and Atsuko Murashima",
year = "2017",
month = "1",
day = "1",
doi = "10.2177/jsci.40.124",
language = "English",
volume = "40",
pages = "124--130",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Neonatal lupus erythematosus

AU - Yokogawa, Naoto

AU - Sumitomo, Naofumi

AU - Miura, Masaru

AU - Shibuya, Kazuhiko

AU - Nagai, Hiroshi

AU - Goto, Mikako

AU - Murashima, Atsuko

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Neonatal lupus (NL), a passively-acquired autoimmune disease associated with maternal anti-SSA antibody, presents both cardiac manifestations such as cardiac NL and non-cardiac manifestations including rashes, cytopenia, and hepatic abnormalities. Cardiac NL, occurring in 1-2% of anti-SS-A antibody-positive mothers, is a life-threatening complication with a mortality rate of 20% and a pacemaker implantation rate of 70%. In contrast, cutaneous NL, which is more common than cardiac NL, usually resolves in six months. Since half of NL cases occur in asymptomatic mothers, if an infant presents characteristic cutaneous or cardiac manifestations of NL, the mother should be tested for anti-SS-A antibody. In mothers positive for anti-SS-A antibody, the risk of having a child with cardiac NL increases ten-fold and five-fold for a previous child with cardiac NL and cutaneous NL, respectively. A joint American, British, and French retrospective study of NL registries showed that hydroxychloroquine (HCQ) reduced the cardiac NL risk in subsequent pregnancies in mothers who previously had a child with cardiac NL. A prospective open-label study to confirm this effect is being undertaken in the USA. A similar prospective multi-center study will be undertaken in Japan. Establishing a Japanese registry of children with NL and subsequent pregnancies of their mothers will help promote clinical research in NL in Japan.

AB - Neonatal lupus (NL), a passively-acquired autoimmune disease associated with maternal anti-SSA antibody, presents both cardiac manifestations such as cardiac NL and non-cardiac manifestations including rashes, cytopenia, and hepatic abnormalities. Cardiac NL, occurring in 1-2% of anti-SS-A antibody-positive mothers, is a life-threatening complication with a mortality rate of 20% and a pacemaker implantation rate of 70%. In contrast, cutaneous NL, which is more common than cardiac NL, usually resolves in six months. Since half of NL cases occur in asymptomatic mothers, if an infant presents characteristic cutaneous or cardiac manifestations of NL, the mother should be tested for anti-SS-A antibody. In mothers positive for anti-SS-A antibody, the risk of having a child with cardiac NL increases ten-fold and five-fold for a previous child with cardiac NL and cutaneous NL, respectively. A joint American, British, and French retrospective study of NL registries showed that hydroxychloroquine (HCQ) reduced the cardiac NL risk in subsequent pregnancies in mothers who previously had a child with cardiac NL. A prospective open-label study to confirm this effect is being undertaken in the USA. A similar prospective multi-center study will be undertaken in Japan. Establishing a Japanese registry of children with NL and subsequent pregnancies of their mothers will help promote clinical research in NL in Japan.

KW - Anti-SS-A antibody

KW - Congenital heart block

KW - Hydroxychloroquine

KW - Neonatal cutaneous lupus erythematosus

KW - Neonatal lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85020642421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020642421&partnerID=8YFLogxK

U2 - 10.2177/jsci.40.124

DO - 10.2177/jsci.40.124

M3 - Article

C2 - 28603203

AN - SCOPUS:85020642421

VL - 40

SP - 124

EP - 130

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 2

ER -